Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells

Journal of Endocrinological Investigation

Volumn 36, Issue 11, 2013, Pages 1020-1026

  Crescioli, C ^a   Sturli, N ^b   Sottili, M ^b   Bonini, P ^b   Lenzi, A ^c   Di Luigi, L ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Insulin; Insulin resistance; Metabolism; PDE5i; Skeletal muscle cells

Indexed keywords

CITRATE SYNTHASE; FATTY ACID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; LACTIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SUCCINATE DEHYDROGENASE; TADALAFIL;

ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CGMP ASSAY; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; INSULIN LIKE ACTIVITY; MALE; METABOLIC REGULATION; MTT ASSAY; MUSCLE CELL; MUSCLE METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TOXICITY TESTING; WESTERN BLOTTING;

CARBOLINES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SKELETAL; PHOSPHODIESTERASE 5 INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84891703823     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/9034     Document Type: Article

References (34)

1. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004, 1: 292-300.
2. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007, 56: 1025-33.
3. De Fronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIIDM. A balanced overview. Diabetes Care 1992, 15: 318-68.
4. Young ME, Leighton B. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J 1998, 329: 73-9.
5. Sabatini S, Sgrò P, Duranti G, Ceci R, Di Luigi L. Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Pol 2011, 58: 237-41.
6. Guidetti L, Emerenziani GP, Gallotta MC, Pigozzi F, Di Luigi L, Baldari C. Effect of tadalafil on anaerobic performance indices in healthy athletes. Br J Sports Med 2008, 42: 130-3.
7. Crescioli C, Sottili M, Bonini P, et al. Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol 2012, 91: 9-49.
8. Flores Rodríguez J, Berzas Nevado JJ, Castañeda Peñalvo G, Mora Diez N. Development of a micellar electrokinetic capillary chromatography method for the determination of three drugs employed in the erectile dysfunction therapy. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 811: 231-6.
9. Cheng CL, Chou CH. Determination of Tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 822: 278-84.
10. Sottili M, Cosmi L, Borgogni E, et al. Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells. Exp Cell Res 2009, 315: 264-73.
11. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW. Biochemical assays of respiratory chain complex activity. Methods Cell Biol 2007, 80: 93-119.
12. Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007, 195: 145-55.
13. Crescioli C, Squecco R, Cosmi L, et al. Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp Cell Res 2008, 314: 1337-50.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25: 402-8.
15. Alessi DR, Downes CP. The role of PI 3-kinase in insulin action. Biochim Biophys Acta 1998, 1436: 151-64.
16. Vandromme M, Rochat A, Meier R, et al. Protein kinase B beta/Akt2 plays a specific role in muscle differentiation. J Biol Chem 2001, 276: 8173-9.
17. Virkamäki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999, 103: 931-43.
18. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002, 12: 9-18.
19. Al-Khalili L, Krämer D, Wretenberg P, Krook A. Human skeletal muscle cell differentiation is associated with changes in myogenic markers and enhanced insulin-mediated MAPK and PKB phosphorylation. Acta Physiol Scand 2004a, 180: 395-403.
20. Al-Khalili L, Chibalin AV, Yu M, et al. MEF2 activation in differentiated primary human skeletal muscle cultures requires coordinated involvement of parallel pathways. Am J Physiol Cell Physiol 2004, 286: C1410-6.
21. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378: 785-9.
22. McManus EJ, Sakamoto K, Armit LJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005, 24: 1571-83.
23. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003, 278: 51606-12.
24. Peterson CW, Ayer DE. An extended Myc network contributes to glucose homeostasis in cancer and diabetes. Front Biosci 2011, 17: 2206-23.
25. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002, 90: 11G-8G.
26. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452: 181-6.
27. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis . Essential role of nitric oxide signaling. J Biol Chem 2005, 280: 12944-55.
28. Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol 2008, 53: 1282-8.
29. Mostafa T, Rashed LA, Kotb K. Testosterone and chronic sildenafil/tadalafil anti-apoptotic role in aged diabetic rats. Int J Impot Res 2010, 22: 255-61.
30. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Net Med 2005, 11: 214-22.
31. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003, 92: 596-7.
32. Giannetta E, Isidori AM, Galea N, et al. Chronic inhibition of cGMP phosphodiesterase 5 improbe diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012, 125: 2323-33.
33. Kukreja RC, Salloum FN, Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol 2012, 59: 1921-7.
34. Jansson PA, Murdolo G, Sjogren L, et al. Tadalafil increases muscle capillary recruitment and forearm glucose uptake in woman with type 2 diabetes. Diabetologia 2010, 53: 2205-8.